Mebendazole Compared with Secnidazole in the Treatment of Adult Giardiasis: A Randomised, No-Inferiority, Open Clinical Trial

Table 2

Parasitological response and adverse events reported after treatment.

	MBZ		SNZ		Estimated differences	95% IC of difference (𝐼1−𝛼)
	No.	%	No.	%	between MBZ-SNZ	[−1,𝑃𝑠−𝑃𝑒+𝑍^∗1−𝛼SE]
Efficacy
Patients with parasitological cure	*55/64	85.9	56/62	90.3	−4.4%	[−1,0.14]
	**55/62	88.7	56/61	91.8	−3.1%	[−1,0.12]
Safety
Patients with at least one adverse event	15/64	23.4	20/62	32.3	−8.9%	(−26.0;8.4)
Type of events adverse reported
Abdominal pain	12 (18.7)		14 (22.6)
Nausea	5 (7.8)		4 (6.4)
Bitter taste	2 (3.1)		15 (24.1)
Diarrhoea	2 (3.1)		3 (4.8)
Dizziness	0 (0)		6 (9.6)

*Intention-to-treat analysis for the no inferiority.
** Per-protocol analysis for the no inferiority.